Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.

BMJ open - 6 Jan 2016

Molfino Nestor A, Kuna Piotr, Leff Jonathan A, Oh Chad K, Singh Dave, Chernow Marlene, Sutton Brian, Yarranton Geoffrey

Abstract excerpt

OBJECTIVES: We wished to evaluate the effects of an antigranulocyte-macrophage colony-stimulating factor monoclonal antibody (KB003) on forced expiratory volume in 1 s (FEV1), asthma control and asthma exacerbations in adult asthmatics inadequately controlled by long-acting bronchodilators and inhaled/oral corticosteroids. SETTINGS: 47 ambulatory asthma care centres globally. PRIMARY OUTCOME MEASURES: Change in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Anti-Asthmatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asthma

Share to Bronchodilator Agents

Share to Eosinophils

Share to Forced Expiratory Volume

Share to Granulocyte-Macrophage Colony-Stimulating Factor

Share to Infusions, Intravenous

Source

Open in PubMed Open full text

Identifiers

PMID: 26739717
DOI: 10.1136/bmjopen-2015-007709
PMCID: PMC4716197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.PMID 26739717Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Monoclonal Antibodies in Idiopathic Chronic Eosinophilic Pneumonia: A Scoping ReviewSemantic proximity Read ↗

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic PhenotypeSemantic proximity Read ↗

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Benralizumab: The Immuno-Pharmacological State of the ArtSemantic proximity Read ↗

Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H4 R-antagonist (JNJ-39758979) in adults with uncontrolled asthma.Semantic proximity Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read ↗

Eosinophil Counts in Adults with Asthma Treated with Anti-IL-4Rα Rademikibart in a Randomized TrialSemantic proximity Read ↗

Mepolizumab for COPD with Eosinophilic Phenotype following HospitalizationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.